OncoMatch

OncoMatch/Colorectal Cancer (CRC)/MSH6

Colorectal Cancer (CRC)MSH6 Clinical Trials

32 recruiting trials·Updated daily from ClinicalTrials.gov

MSH6 loss by IHC defines dMMR status and MSI-H eligibility for checkpoint immunotherapy in colorectal cancer. MSH6 deficiency can result from germline Lynch syndrome mutations or somatic inactivation. Trials for dMMR/MSI-H CRC broadly enroll MSH6-deficient patients, who benefit from pembrolizumab, nivolumab, and combination PD-1/CTLA-4 inhibition.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting MSH6 Colorectal Cancer (CRC) trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 3

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

Jun Huang

Phase 2/Phase 3

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Sun Yat-sen University

Phase 3

Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer

Sir Run Run Shaw Hospital

Phase 3

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Sun Yat-sen University

Phase 2/Phase 3

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 3

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

National Cancer Institute, Naples

Additional trials

More MSH6 Colorectal Cancer (CRC) trials

See all in search →
Phase 2
NCT06992258A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal CancerPhase 29 US sitesNCT07079631A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal CancerPhase 1/Phase 24 US sitesNCT06529523Tislelizumab in People With Colorectal CancerPhase 21 US siteNCT06959550Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal CancerPhase 21 US siteNCT05411718A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch SyndromePhase 21 US siteNCT06265285Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramPhase 21 US site
18 international trials (no US sites)
NCT06923345Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)Phase 2NCT06698757Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal CancerPhase 2NCT05970302XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRCPhase 2NCT04920149Mesalamine for Colorectal Cancer Prevention Program in Lynch SyndromePhase 2NCT05229003Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCPhase 2NCT06856837- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver MetastasesPhase 2NCT07347951A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal CancerPhase 2NCT06580574Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon CancersPhase 2NCT07068763Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal CancerPhase 2NCT06204094Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal CancerPhase 2NCT06002789Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCCPhase 2NCT06722183Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor EntitiesPhase 2NCT05954429A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyPhase 2NCT07279077Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II TrialPhase 2NCT06922383A Clinical Study of Arfolitixorin in Patients With mCRCPhase 1/Phase 2NCT05310643Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCPhase 2NCT06949111Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）Phase 2NCT07198165SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARCPhase 2
Other Colorectal Cancer (CRC) biomarkers

Browse other molecular targets with active Colorectal Cancer (CRC) trials.

KRASNRASBRAFMSH2MMR / MSI-HPMS2MLH1HER2 (ERBB2)EGFR
← All Colorectal Cancer (CRC) clinical trials